United States Patent 5,627,178: Scope, Claim Strength, and US Landscape for 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine

US 5,627,178 covers therapeutic use of the specific small molecule 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine and its acid addition salts across a broad set of psychosis-spectrum disorders and anxiety disorders, with an explicit 1 to 20 mg/day dosing window in multiple dependent claims. The claims are written as method-of-treatment claims, tying infringement to administering the claimed compound (or acid addition salt) in an effective amount for listed indications and, in some claims, with a numeric dose limitation.

What exactly is the claimed active and what form is covered?

Across claims 1 through 3 and 5 through 10, the operative element is:

Drug substance: 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine
Salt coverage: “acid addition salt thereof”
Core actus reus: “comprising administering to a patient … an effective amount” (claims 1, 5, 8) or a constrained effective amount (claims 4, 6, 10)

Impact on scope: The claim construction boundary is not the specific target receptor or mechanism; it is the specific molecule (and its acid addition salts) used for the listed disorders. That structure typically produces a narrow chemical coverage (only that compound and acid addition salts), paired with broad indication language.

How broad is the clinical indication coverage?

Claim set map (indications by claim number)

Claim	Indication category	Included disorders (as listed)	Coverage type
1	Psychosis-spectrum disorders	Schizophrenia (all listed subtypes and stages), Delusional (Paranoid) Disorder, Brief Reactive Psychosis, Schizophreniform Disorder, Schizoaffective Disorder, Induced Psychotic Disorder, Psychotic Disorder NOS (Atypical Psychosis), Bipolar (mixed/manic/depressed) with psychotic features, Major Depression (single episode) with psychotic features	Patient method
2	Same psychosis list as claim 1 (dependent layering)	Mirrors claim 1 list	Dependent on claim 1
3	Truncated psychosis list vs claim 1/2	Includes schizophrenia subtypes/stages and Delusional (Paranoid), Brief Reactive Psychosis, Schizophreniform, Schizoaffective	Dependent layering
5	Anxiety disorders	Psychoactive Substance Anxiety Disorder; Organic Anxiety Disorder; Obsessive Compulsive Disorder; Post-traumatic Stress Disorder; Generalized Anxiety Disorder; Anxiety Disorder NOS	Patient method
7	Same anxiety list but adds “treating an animal, including a human”	Organic Anxiety Disorder; Obsessive Compulsive Disorder; Post-traumatic Stress Disorder; Generalized Anxiety Disorder; Anxiety Disorder NOS	Animal method
8	“Pathologic psychological condition” defined by consistent manifestations	Conditions where delusions, hallucinations, disorganized behavior, or anxiety are consistent manifestations	Patient method with functional definition
9	Dependent functional subset	delusions/hallucinations/disorganized behavior consistent manifestations	Dependent on 8
10	Dependent on 8 with dose range	same functional definition	Dose-limited patient method

Practical implication

Claims 1-3 are indication-heavy: the long enumerations expand the number of labeled disease contexts that could satisfy “a condition selected from the group consisting of …” while still requiring the same drug.
Claim 8 broadens beyond enumerated DSM labels by using a manifestation-based definition (“delusions, hallucinations, disorganized behavior, or anxiety are a consistent manifestation”), which can capture off-label clinical presentations even when the formal diagnosis name is not in the list.

What is the effective-dose scope and where is it fixed?

Dose-limited claims

Claim	Dose limitation language	Dose coverage
4 (dependent of 1)	“effective amount is from 1 to 20 mg per day”	Enforces numeric daily amount
6 (dependent of 5)	“effective amount is from 1 to 20 mg per day”	Enforces numeric daily amount
10 (dependent of 8)	“effective amount is from 1 to 20 mg per day”	Enforces numeric daily amount

Non-dose-limited method claims

Claims 1-3 and 5, 7, 8, 9 do not include a numeric dose range. They require only an “effective amount.”

Impact on enforceability strategy

A competitor that uses this compound for one of the listed indications but with a dose outside 1 to 20 mg/day could still land in the scope of non-dose-limited claims (1, 2, 3, 5, 7, 8, 9), depending on how “effective amount” is proven for infringement.
Conversely, numeric dosing claims anchor a clearer infringement window for claims 4, 6, 10.

What is the claim architecture: independent vs dependent and how that shapes infringement?

Independent claims in the provided set

The excerpt shows claim 1 and then claim 2 as “A method of claim 1…,” indicating claim 1 is the independent anchor for the psychosis list.

Similarly:

Claim 5 depends from claim 1’s drug framework but is written independently as “A method of claim 5…” appears later (claim 6), so claim 5 is likely an independent claim for anxiety.
Claim 8 appears as an independent functional manifestation-based method.
Claims 4, 6, 9, 10 are dependent on their respective base claims.

Legal effect (practical)

Claim 1: provides the broadest psychosis indication coverage without numeric dose limitation.
Claim 2 and claim 3: narrow by dependency and, in claim 3, by a shorter disorder list than claim 2/1. Dependency can still matter because infringement of claim 3 requires all features of claim 8? (No, claim 3 is dependent on claim 2) plus that claim’s specific listed subset.
Claim 5: anxiety disorders enumeration without numeric dose in claim 5.
Claim 8: a functional-in-manifestation claim that can be argued to cover clinical syndromes even if diagnosis is not one of the named DSM-ish labels.

What does the “comprising” language cover and what does it exclude?

The operative “comprising administering” phrasing means:

The method includes administering the claimed compound in an effective amount.
It does not exclude additional therapeutic agents administered concurrently. The claim does not require monotherapy.

Implication: Combination regimens that include this compound could still infringe if the other steps do not remove the requirement that the clinician administers the claimed compound in the effective amount for the covered condition.

How are “patients” vs “animals” handled?

Claim 1, 5, 8, 9, 10 target “a patient.”
Claim 7 expands to “an animal, including a human,” and lists a subset of anxiety disorders.

Implication: This eliminates an argument that the method claims only cover human administration.

Where does functional language create scope leverage?

Claim 8 functional definition

Claim 8 covers a patient with “a pathologic psychological condition wherein delusions, hallucinations, disorganized behavior, or anxiety are a consistent manifestation.”

Key scope drivers:

“pathologic psychological condition” is not strictly tied to DSM label names.
“wherein” creates a clinical-pathology relationship element: the manifestation must be consistent.

Claim 9 further constrains by specifying:

“delusions, hallucinations, or disorganized behavior are a consistent manifestation.”

Implication: Claim 8/9 can be broader than the enumerated disease lists if clinical evidence supports “consistent manifestation,” even for conditions that do not fit the enumerated group lists.

Patent landscape: what can you infer from the claim structure alone?

The excerpt provides the claims and drug identity but does not provide:

the filing date, priority claims, or prosecution history,
the patent’s expiration schedule in the US (including any PTA),
cited prior art, examiner rejections, or claim amendments.

Because those elements are required to produce a precise US “landscape” (including which families are blocking, which patents are likely coextensive, and which later filings may still be enforceable), a complete landscape cannot be constructed from claim text alone without introducing unsupported assertions.

What can be stated directly from the claim language:

Core competitive risk profile

Any product that does all of the following simultaneously would create the highest infringement risk:

Uses 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine or an acid addition salt; and
Administers it to treat a condition within the enumerated lists (psychosis-spectrum or anxiety disorders); and
If relying on claims 4/6/10, uses dosing aligned to 1 to 20 mg/day.

Likely design-around levers (textual)

Different active (not this compound and not an acid addition salt) avoids the drug-identity requirement.
Avoidance of the defined indication may reduce likelihood of literal infringement; however, claim 8’s manifestation-based definition makes purely diagnosis-based design-around less robust.
Dose: using outside 1 to 20 mg/day may avoid claims 4/6/10 but not necessarily avoid claims without numeric dosing.

Claim-by-claim infringement checklist

Claim 1 (psychosis method, broad)

Infringement requires:

Drug: the specific compound or acid addition salt
Condition: “selected from the group consisting of” the listed psychosis-related disorders, including the long schizophrenia subtype/stage matrix plus specified psychoses and mood-psychosis entities
Effective amount: no numeric range

Claim 4 (psychosis + dose band)

All of claim 1 plus:

Dose: 1 to 20 mg/day

Claim 5 (anxiety method, enumerated)

Drug: compound or acid addition salt
Condition: selected from the anxiety list (psychoactive substance anxiety disorder; organic anxiety disorder; OCD; PTSD; GAD; anxiety disorder NOS)
Effective amount: no numeric range

Claim 6 (anxiety + dose band)

All of claim 5 plus:

Dose: 1 to 20 mg/day

Claim 7 (animal method for anxiety subset)

Drug: compound or acid addition salt
Treats an animal including a human
Condition: “selected from” the subset (organic anxiety disorder; OCD; PTSD; GAD; anxiety disorder NOS)
No numeric dose

Claim 8 (functional manifestation-based psychiatric condition)

Drug: compound or acid addition salt
Condition: pathologic psychological condition where delusions/hallucinations/disorganized behavior/anxiety are consistent manifestations
Effective amount: no numeric range

Claim 9 (functional manifestation subset)

All of claim 8 plus:

delusions/hallucinations/disorganized behavior are consistent manifestations

Claim 10 (functional + dose band)

All of claim 8 plus:

Dose: 1 to 20 mg/day

Key Takeaways

US 5,627,178 is a method-of-treatment patent that covers one specific active ingredient (and acid addition salts) used to treat psychosis-spectrum disorders (claims 1-3) and anxiety disorders (claims 5-7), with a manifestation-based psychiatric condition pathway (claims 8-10).
Breadth is driven by indication enumeration (claims 1-3, 5, 7) and functional clinical framing (claims 8-9).
Numeric dose exposure exists in dependent claims only: 1 to 20 mg/day in claims 4, 6, 10; other claims require only an “effective amount.”
Without filing/priority and prosecution data, the complete US patent landscape (blocking patents, expiration timing, co-pending families) cannot be stated from the claims alone.

FAQs

1) Does the patent cover the drug by generic class or only a specific structure?

It covers the specific molecule 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine and its acid addition salts, not a broad class.

2) What psychiatric indications are explicitly listed for psychosis?

Claim 1 lists schizophrenia subtypes and stages (catatonic, disorganized, paranoid, undifferentiated, residual across multiple course states), plus delusional disorder, brief reactive psychosis, schizophreniform disorder, schizoaffective disorder, induced psychotic disorder, psychotic disorder NOS, and bipolar and major depression with psychotic features.

3) Is there a numeric dosing limitation?

Yes, but only in dependent claims: 1 to 20 mg per day appears in claims 4, 6, and 10.

4) Can it apply beyond DSM-like diagnosis labels?

Yes. Claims 8 and 9 use a manifestation-based definition (delusions, hallucinations, disorganized behavior, or anxiety as consistent manifestations), which can extend beyond the enumerated disorder names.

5) Does combination therapy avoid infringement?

No. The claim uses “comprising administering,” which permits additional steps or co-therapies while still meeting the requirement to administer the claimed compound in an effective amount for the covered condition.

References

United States Patent No. 5,627,178. “Method of treatment using 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine and acid addition salts.” (Claims provided in prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0454436	⤷ Start Trial	CA 2001 00042	Denmark	⤷ Start Trial
European Patent Office	0454436	⤷ Start Trial	C970015	Netherlands	⤷ Start Trial
European Patent Office	0454436	⤷ Start Trial	SPC/GB96/058	United Kingdom	⤷ Start Trial
European Patent Office	0454436	⤷ Start Trial	97C0012	Belgium	⤷ Start Trial
European Patent Office	0454436	⤷ Start Trial	9/1997	Austria	⤷ Start Trial
Austria	127804	⤷ Start Trial
Australia	643267	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,627,178

Summary for Patent: 5,627,178